Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors

Abdülrezzak, Ümmühan; Kurt, Yurdagul K.; Kula, Mustafa; Tutuş, Ahmet

doi:10.1097/mnm.0000000000000522

Cited by 44 publications

(60 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Total 68 Ga-DOTATATE uptake in NETs was reported in the past in a series of patients, but not in specific subtypes of NET, and no correlation analysis with tumor biomarkers was reported [12,13]. Moreover, the correlations between tumor biomarkers and tumor burden reported in the past have been based on anatomical imaging[19], counting the number of lesions[10], presence/absence of liver metastases[25] and not based on accurate total tumor volume measurements, as performed in the current analysis.…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, no study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using the new generation DOTA-peptide based PET/CT imaging [12,13]. Thus, in this study we analyzed the correlation between biochemical biomarkers of NETs and total 68 Ga-DOTATATE-avid tumor volume (TV), as a measure of total tumor burden in patients with NET.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements

Tirosh

Papadakis

Millo

et al. 2017

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective To determine the association between neuroendocrine tumor (NET) biomarker levels and extent of disease as assessed by 68Ga DOTATATE PET/CT imaging. Design A retrospective analysis of a prospective database of patients with NETs. Methods Fasting plasma chromogranin A (CgA), neuron-specific enolase (NSE), gastrin, glucagon, vasoactive intestinal peptide (VIP) and pancreatic polypeptide (PP), and 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) levels were measured. Correlation between biomarkers and total 68Ga-DOTATATE-avid tumor volume (TV) was analyzed. Results The analysis included 232 patients. In patients with pancreatic NETs (n=112), 68Ga-DOTATATE TV correlated with CgA (r=0.6, p=0.001, Spearman). In patients with multiple endocrine neoplasia type 1 (n=39), 68Ga-DOTATATE TV correlated with glucagon (r=0.5, p=0.02) and PP levels (r=0.5, p=0.049). In patients with von Hippel-Lindau (n=24), plasma VIP (r=0.5, p=0.02) and PP levels (r=0.7, p<0.001) correlated with 68Ga-DOTATATE TV. In patients with small intestine NET (SINET, n=74), 68Ga-DOTATATE TV correlated with CgA (r=0.5, p=0.02) and 5-HIAA levels (r=0.7, p<0.001), with 5-HIAA ≥8.1 mg/24h associated with metastatic disease with high positive (81.8%) and negative (85.7%) predictive values (p=0.001). 68Ga-DOTATATE TV in patients with NET of unknown primary (n=16) and those with NET of other primary location (n=30) correlated with 5-HIAA levels (r=0.8, p=0.002, and r=0.7, p=0.02, respectively). Conclusions Our data supports the use of specific NET biomarkers based on the site of the primary NET and the presence of hereditary syndrome-associated NET. High urinary 5-HIAA levels indicate the presence of metastatic disease in patients with SINET.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements

Tirosh

Papadakis

Millo

et al. 2017

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Abdulrezzak et al [52] gave a contribution to the combined imaging approach with [ 68 Ga]Ga-DOTA-TATE and [ 18 F]FDG by measuring several volumetric parameters instead of SUV max only, as there are many factors that can influence this parameter. These new parameters are the metabolic tumor volume (MTV) and the total lesion glycolysis (TLG) values in [ 18 F]FDG PET/CT), the somatostatin receptor density (SRD) and the total lesion somatostatin receptor expression (TLSRE) values in [ 68 Ga]Ga-DOTA-TATE PET/CT.…”

Section: Combined [68ga]ga-dota-sst Analogues and [18f]fdg Pet/ct mentioning

confidence: 99%

Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

Carideo

Prosperi

Panzuto

et al. 2019

JCM

View full text Add to dashboard Cite

Gastro-entero-pancreatic neuroendocrine neoplasia (GEP-NENs) are rare tumors, but their frequency is increasing. Neuroendocrine tumors normally express somatostatin (SST) receptors (SSTR) on cell surface, especially G1 and G2 stage tumors, but they can show a dedifferentiation in their clinical history as they become more aggressive. Somatostatin receptor imaging has previously been performed with a gamma camera using [111In]In or [99mTc]Tc-labelled compounds, while [68Ga]Ga-labelled compounds and PET/CT imaging has recently become the gold standard for the diagnosis and management of these tumors. Moreover, in the last few years 18F-fluorodeoxyglucose ([18F]FDG) PET/CT has emerged as an important tool to define tumor aggressiveness and give relevant prognostic information, particularly when coupled with [68Ga]Ga-labelled SST analogues PET/CT. This review focuses on the importance of combined imaging with [68Ga]Ga-labelled SST analogues and [18F]FDG for the management of GEP-NENs.

show abstract

“…These 18 F-FDG PET/CT parameters also correlate with PFS, OS and in one study had a sensitivity and specificity for differentiating G1/G2 tumors form G3 of 100% and 62%, respectively(Table 6). A number of studies have concluded that the results of 18 F-FDG PET/CT and 68 Ga-DOTA-SSA PET/CT provide complementary information that is clinical relevant[24,136,142–145]. Recent studies[139,140] have extended this principal of the complementariness of these to nuclear medicine imaging studies to recommend a NETPET score be assigned to NETs based on the result of these two studies that could have important prognostic value and help select better therapeutic options.…”

Section: Molecular Imaging In Pannets(table 2) (Fig 1)mentioning

confidence: 99%

Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies

Lee

Ito

Jensen

2018

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Recently, there have been a number of advances in imaging pancreatic neuroendocrine tumors (panNETs), as well as other neuroendocrine tumors (NETs), which have had a profound effect on the management and treatment of these patients, but in some cases are also associated with controversies. Areas covered: These advances are the result of numerous studies attempting to better define the roles of both cross-sectional imaging, endoscopic ultrasound, with or without fine-needle aspiration, and molecular imaging in both sporadic and inherited panNET syndromes; the increased attempt to develop imaging parameters that correlate with tumor classification or have prognostic value; the rapidly increasing use of molecular imaging in these tumors and the attempt to develop imaging parameters that correlate with treatment/outcome results. Each of these areas and the associated controversies are reviewed. Expert commentary: There have been numerous advances in all aspects of the imaging of panNETs, as well as other NETs, in the last few years. The advances are leading to expanded roles of imaging in the management of these patients and the results being seen in panNETs/GI-NETs with these newer techniques are already being used in more common tumors.

show abstract

Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors

Cited by 44 publications

References 23 publications

Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements

Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements

Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review

Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies

Contact Info

Product

Resources

About